Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD

Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F, Rheault, Tara, MacDonald-Berko, Margot, Bengtsson, Thomas, Rickard, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392818/
https://www.ncbi.nlm.nih.gov/pubmed/37533771
http://dx.doi.org/10.2147/COPD.S413436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392818/
https://www.ncbi.nlm.nih.gov/pubmed/37533771
http://dx.doi.org/10.2147/COPD.S413436

Ejemplares similares